VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CVN424
Phase 3
Small molecule
C
Cerevance Beta, Inc.
1
Indications
5
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Parkinson's Disease
2 trials
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Completed
·
C
Cerevance Beta, Inc.
·
Phase 2
·
NCT04191577
·
136 enrolled
Early Parkinson's Disease Monotherapy With CVN424
Completed
·
C
Cerevance Beta, Inc.
·
Phase 2
·
NCT06006247
·
64 enrolled
Complication
1 trial
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Recruiting
·
C
Cerevance
·
Phase 3
·
NCT06553027
·
330 enrolled
Unspecified
2 trials
Relative Bioavailability and Food Effect Study of CVN424
Completed
·
C
Cerevance Beta, Inc.
·
Phase 1
·
NCT05635461
·
32 enrolled
Study of CVN424 in Healthy Subjects
Completed
·
C
Cerevance Beta, Inc.
·
Phase 1
·
NCT03657030
·
64 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
5 trial records for CVN424. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CVN424 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CVN424. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Cerevance Beta, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
C
Cerevance Beta, Inc.
Related News